Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

2025-523297-16-00 Protocol 95566692LYM1001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 27 Feb 2026 · Status Ongoing, recruiting · 2 EU/EEA countries · 6 sites · Protocol 95566692LYM1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 108
Countries 2
Sites 6

Non-Hodgkin Lymphoid Malignancies (NHLs)

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Feb 2026 → ongoing
Decision date (initial)
2026-02-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Hodgkin Lymphoid Malignancies (NHLs)

VersionLevelCodeTermSystem organ class
28.0 PT 10012818 Diffuse large B-cell lymphoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

2 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 13 2
France Authorised, recruitment pending 24 4
Rest of world
Turkey, Australia
71

Investigational sites

Belgium

2 sites · Ongoing, recruiting
Universitair Ziekenhuis Antwerpen
Hematology, Drie Eikenstraat 655, 2650, Edegem
Centre hospitalier universitaire de Liege
Hematology, Avenue De L'Hopital 1, 4000, Liege

France

4 sites · Authorised, recruitment pending
Assistance Publique Hopitaux De Paris
Clinical hematology & cellular therapy, Num Voie 47 A 83, 47 Boulevard De L Hopital, Paris
Oncopole Claudius Regaud
Hematology, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Centre Hospitalier Universitaire De Lille
Blood diseases, Rue Michel Polonowski, 59000, Lille
Hospices Civils De Lyon
Hematology, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2026-02-27 2026-03-13

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-08 Belgium Acceptable
2026-02-26
2026-02-26
2 SUBSEQUENT ADDITION OF MSC APP-2 2026-03-11 Acceptable
2026-02-26
2026-05-21